Přínos přípravků proti vaskulárnímu endotelovému růstovému faktoru v oftalmologii
| Title in English | Benefit of anti-vascular endothelial growth factor treatment in ophthalmology |
|---|---|
| Authors | |
| Year of publication | 2018 |
| Type | Article in Periodical |
| Magazine / Source | Farmakoterapeutická revue |
| MU Faculty or unit | |
| Citation | |
| Keywords | ranibizumab; aflibercept; wet form of age related macular degeneration; diabetic macular oedema; retinal vein occlusion; neovascular choroidal membrane |
| Description | Anti-vascular endothelial growth factor (VEGF) preparations are among the latest ophthalmic treatments. These preparations are used in the treatment of wet form of age-related macular degeneration, treatment of diabetic macular edema, macular edema due to retinal vein occlusion, and treatment of secondary choroidal neovascularization in pathological myopia or other diseases. Currently two preparations are available - ranibizumab (Lucentis, Novartis) and aflibercept (Eylea, Bayer). Ranibizumab is a recombinant humanized monoclonal antibody fragment against VEGF. Aflibercept (Eylea, Bayer) is a fusion protein consisting of extracellular domains of human VEGF receptor 1 and 2 and a human IgG fragment (the so-called false receptor). Both preparations reduce the proliferation of endothelial cells, reduce vascular permeability of the vessels, and block the formation of new blood vessels. Substances are applied in topical anesthesia to the vitreous body, repeated application is necessary. The treatment is covered by health insurance and is concentrated in specialized centres. |